Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Author Correction: Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.

Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, Walter TS, O'Callaghan CA, Borrow P, Toebes M, Hansen SG, Sacha JB, Abdulhaqq S, Greene JM, Früh K, Marshall E, Picker LJ, Jones EY, McMichael AJ, Gillespie GM.

Nat Commun. 2018 Nov 13;9(1):4833. doi: 10.1038/s41467-018-07304-9.

2.

Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth.

Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, Hraber PT, Decker TG, Smith AG, Gondim MV, Gillis L, Wandzilak J, Chuang GY, Rawi R, Cai F, Pellegrino P, Williams I, Overbaugh J, Gao F, Kwong PD, Haynes BF, Shaw GM, Borrow P, Seaman MS, Hahn BH, Korber B.

Cell Rep. 2018 Oct 23;25(4):893-908.e7. doi: 10.1016/j.celrep.2018.09.087.

3.

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses.

Bradley T, Peppa D, Pedroza-Pacheco I, Li D, Cain DW, Henao R, Venkat V, Hora B, Chen Y, Vandergrift NA, Overman RG, Edwards RW, Woods CW, Tomaras GD, Ferrari G, Ginsburg GS, Connors M, Cohen MS, Moody MA, Borrow P, Haynes BF.

Cell. 2018 Oct 4;175(2):387-399.e17. doi: 10.1016/j.cell.2018.08.064. Epub 2018 Sep 27.

4.

Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.

Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, Walter TS, O'Callaghan CA, Borrow P, Toebes M, Hansen SG, Sacha JB, Abdulhaqq S, Greene JM, Früh K, Marshall E, Picker LJ, Jones EY, McMichael AJ, Gillespie GM.

Nat Commun. 2018 Aug 7;9(1):3137. doi: 10.1038/s41467-018-05459-z. Erratum in: Nat Commun. 2018 Nov 13;9(1):4833.

5.

Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection.

Peng BJ, Carlson JM, Liu MKP, Gao F, Goonetilleke N, McMichael AJ, Borrow P, Gilmour J, Heath SL, Hunter E, Bansal A, Goepfert PA.

J Virol. 2018 Sep 12;92(19). pii: e00711-18. doi: 10.1128/JVI.00711-18. Print 2018 Oct 1.

6.

Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.

Partridge T, Nicastri A, Kliszczak AE, Yindom LM, Kessler BM, Ternette N, Borrow P.

Front Immunol. 2018 Apr 27;9:912. doi: 10.3389/fimmu.2018.00912. eCollection 2018.

7.

Adaptive Reconfiguration of Natural Killer Cells in HIV-1 Infection.

Peppa D, Pedroza-Pacheco I, Pellegrino P, Williams I, Maini MK, Borrow P.

Front Immunol. 2018 Mar 16;9:474. doi: 10.3389/fimmu.2018.00474. eCollection 2018.

8.

HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction.

Gargan S, Ahmed S, Mahony R, Bannan C, Napoletano S, O'Farrelly C, Borrow P, Bergin C, Stevenson NJ.

EBioMedicine. 2018 Apr;30:203-216. doi: 10.1016/j.ebiom.2018.03.006. Epub 2018 Mar 9.

9.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

10.

A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesis.

Hassan AS, Hare J, Kamini G, Yindom LM, Kamali A, Karita E, Kilemba W, Price MA, Borrow P, Bjorkman P, Albert J, Kaleebu P, Allan S, Fast P, Hunter E, Gilmour J, Ndung'u T, Rowland-Jones S, Sanders EJ, Esbjornsson J.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.034. doi: 10.1093/ve/vew036.034. eCollection 2017 Mar. No abstract available.

11.

Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, Croom-Carter D, Stacey A, Moss PAH, Hislop AD, Borrow P, Rickinson AB, Bell AI.

J Virol. 2017 Oct 13;91(21). pii: e00382-17. doi: 10.1128/JVI.00382-17. Print 2017 Nov 1.

12.

Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.

Moody MA, Pedroza-Pacheco I, Vandergrift NA, Chui C, Lloyd KE, Parks R, Soderberg KA, Ogbe AT, Cohen MS, Liao HX, Gao F, McMichael AJ, Montefiori DC, Verkoczy L, Kelsoe G, Huang J, Shea PR, Connors M, Borrow P, Haynes BF.

Sci Immunol. 2016 Jul 29;1(1):aag0851. doi: 10.1126/sciimmunol.aag0851. Epub 2016 Jul 29.

13.

Professor Mark Wainberg.

Benkirane M, Berkhout B, Borrow P, Fassati A, Fujii M, Garcia JV, Gorry P, Lever A, Mak J, Nijhuis M, Strebel K, Venter F, Weiss R.

Retrovirology. 2017 May 5;14(1):30. doi: 10.1186/s12977-017-0353-6. No abstract available.

14.

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.

Borrow P, Moody MA.

Immunol Rev. 2017 Jan;275(1):62-78. doi: 10.1111/imr.12504. Review.

15.

Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.

Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG, Barbian HJ, Russell RM, Gondim MV, Bahari CY, Shaw CM, Li Y, Decker T, Haynes BF, Shaw GM, Sharp PM, Borrow P, Hahn BH.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E590-E599. doi: 10.1073/pnas.1620144114. Epub 2017 Jan 9.

16.

Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman Primates.

Keating SM, Heitman JW, Wu S, Deng X, Stacey AR, Zahn RC, de la Rosa M, Finstad SL, Lifson JD, Piatak M Jr, Gauduin MC, Kessler BM, Ternette N, Carville A, Johnson RP, Desrosiers RC, Letvin NL, Borrow P, Norris PJ, Schmitz JE.

J Virol. 2016 Oct 28;90(22):10339-10350. doi: 10.1128/JVI.01061-16. Print 2016 Nov 15.

17.

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.

Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, Kellam P, Finzi A, Borrow P, Hahn BH, Neil SJD.

Cell Host Microbe. 2016 Oct 12;20(4):429-442. doi: 10.1016/j.chom.2016.08.006. Epub 2016 Sep 15.

18.

Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.

Wang C, Hart M, Chui C, Ajuogu A, Brian IJ, de Cassan SC, Borrow P, Draper SJ, Douglas AD.

J Immunol. 2016 Aug 15;197(4):1242-51. doi: 10.4049/jimmunol.1502472. Epub 2016 Jul 13.

19.

HIV-Host Interactions: Implications for Vaccine Design.

Haynes BF, Shaw GM, Korber B, Kelsoe G, Sodroski J, Hahn BH, Borrow P, McMichael AJ.

Cell Host Microbe. 2016 Mar 9;19(3):292-303. doi: 10.1016/j.chom.2016.02.002. Epub 2016 Feb 25. Review.

20.

Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.

Ternette N, Yang H, Partridge T, Llano A, Cedeño S, Fischer R, Charles PD, Dudek NL, Mothe B, Crespo M, Fischer WM, Korber BT, Nielsen M, Borrow P, Purcell AW, Brander C, Dorrell L, Kessler BM, Hanke T.

Eur J Immunol. 2016 Jan;46(1):60-9. doi: 10.1002/eji.201545890. Epub 2015 Nov 4.

21.

Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance.

Deymier MJ, Ende Z, Fenton-May AE, Dilernia DA, Kilembe W, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Sep 17;11(9):e1005154. doi: 10.1371/journal.ppat.1005154. eCollection 2015 Sep.

22.

Viruses transfer the antiviral second messenger cGAMP between cells.

Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, Dong T, Kaever V, Borrow P, Rehwinkel J.

Science. 2015 Sep 11;349(6253):1228-32. doi: 10.1126/science.aab3632. Epub 2015 Jul 30.

23.

Hybrid spreading mechanisms and T cell activation shape the dynamics of HIV-1 infection.

Zhang C, Zhou S, Groppelli E, Pellegrino P, Williams I, Borrow P, Chain BM, Jolly C.

PLoS Comput Biol. 2015 Apr 2;11(4):e1004179. doi: 10.1371/journal.pcbi.1004179. eCollection 2015 Apr.

24.

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.

Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.

25.

Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections.

Armitage AE, Stacey AR, Giannoulatou E, Marshall E, Sturges P, Chatha K, Smith NM, Huang X, Xu X, Pasricha SR, Li N, Wu H, Webster C, Prentice AM, Pellegrino P, Williams I, Norris PJ, Drakesmith H, Borrow P.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12187-92. doi: 10.1073/pnas.1402351111. Epub 2014 Aug 4.

26.

Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.

Tandon R, Chew GM, Byron MM, Borrow P, Niki T, Hirashima M, Barbour JD, Norris PJ, Lanteri MC, Martin JN, Deeks SG, Ndhlovu LC.

AIDS Res Hum Retroviruses. 2014 Jul;30(7):654-64. doi: 10.1089/AID.2014.0004. Epub 2014 May 28.

27.

Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P.

Retrovirology. 2013 Dec 3;10:146. doi: 10.1186/1742-4690-10-146.

28.

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.

Clutton G, Yang H, Hancock G, Sande N, Holloway C, Angus B, von Delft A, Barnes E, Borrow P, Pellegrino P, Williams I, McMichael A, Dorrell L.

Eur J Immunol. 2013 Nov;43(11):2875-85. doi: 10.1002/eji.201343646. Epub 2013 Aug 29.

29.

Monsef Benkirane awarded 2013 Ming K. Jeang Foundation Retrovirology Prize: landmark HIV-1 research honoured.

Berkhout B, Lever A, Wainberg M, Fassati A, Borrow P, Fujii M.

Retrovirology. 2013 Apr 5;10:38. doi: 10.1186/1742-4690-10-38. No abstract available.

30.

Phenotypic properties of transmitted founder HIV-1.

Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP Jr, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33. doi: 10.1073/pnas.1304288110. Epub 2013 Mar 29.

31.

Activation of CCR2+ human proinflammatory monocytes by human herpesvirus-6B chemokine N-terminal peptide.

Clark DJ, Catusse J, Stacey A, Borrow P, Gompels UA.

J Gen Virol. 2013 Jul;94(Pt 7):1624-35. doi: 10.1099/vir.0.050153-0. Epub 2013 Mar 27.

32.

Obituary: Kuan-Teh Jeang.

Berkhout B, Benkirane M, Lever A, Wainberg M, Fassati A, Borrow P, Fujii M, Sriskantharajah S, Cockerill M.

Retrovirology. 2013 Mar 21;10:28. doi: 10.1186/1742-4690-10-28.

33.

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA.

PLoS Pathog. 2013 Feb;9(2):e1003173. doi: 10.1371/journal.ppat.1003173. Epub 2013 Feb 28.

34.

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.

Yates NL, Stacey AR, Nolen TL, Vandergrift NA, Moody MA, Montefiori DC, Weinhold KJ, Blattner WA, Borrow P, Shattock R, Cohen MS, Haynes BF, Tomaras GD.

Mucosal Immunol. 2013 Jul;6(4):692-703. doi: 10.1038/mi.2012.107. Epub 2013 Jan 9.

35.

Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.

Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, Treurnicht F, Hraber P, Riou C, Gray C, Ferrari G, Tanner R, Ping LH, Anderson JA, Swanstrom R; CHAVI Core B, Cohen M, Karim SS, Haynes B, Borrow P, Perelson AS, Shaw GM, Hahn BH, Williamson C, Korber BT, Gao F, Self S, McMichael A, Goonetilleke N.

J Clin Invest. 2013 Jan;123(1):380-93. doi: 10.1172/JCI65330. Epub 2012 Dec 10.

36.

HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44.

Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, Kessler BM, Haynes BF, Bhardwaj N.

J Clin Invest. 2012 Dec;122(12):4685-97. doi: 10.1172/JCI64439. Epub 2012 Nov 19.

37.

Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.

Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J, Zhu LF, Law M, Kneteman N, Tyrrell DL, McKeating JA, Ball JK.

J Virol. 2012 Nov;86(22):11956-66. doi: 10.1128/JVI.01079-12. Epub 2012 Aug 1.

38.

Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors.

Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, Baalwa J, Pellegrino P, Shaw GM, Williams I, Borrow P, Rocha B.

Blood. 2012 May 24;119(21):4928-38. doi: 10.1182/blood-2011-12-395186. Epub 2012 Apr 6.

39.

Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection.

Riou C, Ganusov VV, Campion S, Mlotshwa M, Liu MK, Whale VE, Goonetilleke N, Borrow P, Ferrari G, Betts MR, Haynes BF, McMichael AJ, Gray CM.

J Immunol. 2012 Mar 1;188(5):2198-206. doi: 10.4049/jimmunol.1102813. Epub 2012 Jan 27.

40.

Copy number variation of KIR genes influences HIV-1 control.

Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, Ge D, De Luca A, Martinez-Picado J, Wolinsky SM, Martinson JJ, Jamieson BD, Bream JH, Martin MP, Borrow P, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Carrington M, Goldstein DB, Alter G; NIAID Center for HIV/AIDS Vaccine Immunology.

PLoS Biol. 2011 Nov;9(11):e1001208. doi: 10.1371/journal.pbio.1001208. Epub 2011 Nov 29. Erratum in: PLoS Biol. 2011 Dec;9(12). doi:10.1371/annotation/7e17b146-a69c-4e83-9230-7340486d9dc8.

41.

Inhibition of the type I interferon antiviral response during arenavirus infection.

Borrow P, Martínez-Sobrido L, de la Torre JC.

Viruses. 2010 Nov;2(11):2443-80. doi: 10.3390/v2112443. Epub 2010 Nov 5.

42.

The magnitude and kinetics of the mucosal HIV-specific CD8+ T lymphocyte response and virus RNA load in breast milk.

Mahlokozera T, Kang HH, Goonetilleke N, Stacey AR, Lovingood RV, Denny TN, Kalilani L, Bunn JE, Meshnick SR, Borrow P, Letvin NL, Permar SR; Center for HIV/AIDS Vaccine Immunology.

PLoS One. 2011;6(8):e23735. doi: 10.1371/journal.pone.0023735. Epub 2011 Aug 23.

43.

Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection.

Ganusov VV, Goonetilleke N, Liu MK, Ferrari G, Shaw GM, McMichael AJ, Borrow P, Korber BT, Perelson AS.

J Virol. 2011 Oct;85(20):10518-28. doi: 10.1128/JVI.00655-11. Epub 2011 Aug 10.

44.

Innate immunity in acute HIV-1 infection.

Borrow P.

Curr Opin HIV AIDS. 2011 Sep;6(5):353-63. doi: 10.1097/COH.0b013e3283495996. Review.

45.

Multisite comparison of high-sensitivity multiplex cytokine assays.

Breen EC, Reynolds SM, Cox C, Jacobson LP, Magpantay L, Mulder CB, Dibben O, Margolick JB, Bream JH, Sambrano E, Martínez-Maza O, Sinclair E, Borrow P, Landay AL, Rinaldo CR, Norris PJ.

Clin Vaccine Immunol. 2011 Aug;18(8):1229-42. doi: 10.1128/CVI.05032-11. Epub 2011 Jun 22.

46.

Escape is a more common mechanism than avidity reduction for evasion of CD8+ T cell responses in primary human immunodeficiency virus type 1 infection.

Turnbull EL, Baalwa J, Conrod KE, Wang S, Wei X, Wong M, Turner J, Pellegrino P, Williams I, Shaw GM, Borrow P.

Retrovirology. 2011 Jun 2;8:41. doi: 10.1186/1742-4690-8-41.

47.

Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.

Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, Norris PJ, Kuruc JD, Salazar-Gonzalez JF, Li H, Keele BF, Hicks C, Margolis D, Ferrari G, Haynes B, Swanstrom R, Shaw GM, Hahn BH, Eron JJ, Borrow P, Cohen MS.

PLoS One. 2011 May 10;6(5):e19617. doi: 10.1371/journal.pone.0019617.

48.

Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.

Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ.

AIDS. 2011 Jun 1;25(9):1163-74. doi: 10.1097/QAD.0b013e3283477d67.

PMID:
21505297
49.

Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection.

Ferrari G, Korber B, Goonetilleke N, Liu MK, Turnbull EL, Salazar-Gonzalez JF, Hawkins N, Self S, Watson S, Betts MR, Gay C, McGhee K, Pellegrino P, Williams I, Tomaras GD, Haynes BF, Gray CM, Borrow P, Roederer M, McMichael AJ, Weinhold KJ.

PLoS Pathog. 2011 Feb 10;7(2):e1001273. doi: 10.1371/journal.ppat.1001273.

50.

Reappraisal of the relationship between the HIV-1-protective single-nucleotide polymorphism 35 kilobases upstream of the HLA-C gene and surface HLA-C expression.

Corrah TW, Goonetilleke N, Kopycinski J, Deeks SG, Cohen MS, Borrow P, McMichael A, Brackenridge S.

J Virol. 2011 Apr;85(7):3367-74. doi: 10.1128/JVI.02276-10. Epub 2011 Jan 19.

Supplemental Content

Loading ...
Support Center